Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide

PreclinicalSmall molecule

Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide is one of 25 small molecule programs targeting Central Nervous System Lymphoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Central Nervous System LymphomaActive, not recruiting

Central Nervous System LymphomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

27 competitors in Central Nervous System Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

17 2

Idamycin

Tepadina

Brukinsa

1 5

Temodar

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

6 6

Trexall

Jazz Pharmaceuticals

Phase 2

19 7

Nublexa

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

4 8

Fludara

Sanofi

Phase 2

1 9

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

8 10

Alimta

SShawn Eagle

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

N/ARecruiting

Central Nervous System Lymphoma

NCT07191431

Clinical

Trials by Indication[1]

Central Nervous System Lymphoma1 trial

A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA）

Recruiting·RRuijin Hospital·N/A·NCT07191431·25 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ruijin Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: RRuijin Hospital

Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Central Nervous System Lymphoma1 trial

References

Drug Info

Quick Facts

Related News